RhumbLine Advisers
TMDX icon

RhumbLine Advisers’s Transmedics TMDX Stock Holding History

RhumbLine Advisers’s Portfolio TMDX Stock Details TMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.93M Buy
89,824
+1,788
+2% +$233K 0.01% 1114
2025
Q4 		$10.7M Sell
88,036
-5,306
-6% -$666K 0.01% 1030
2025
Q3 		$10.5M Buy
93,342
+125
+0.1% +$14.6K 0.01% 1062
2025
Q2 		$12.5M Buy
93,217
+3,693
+4% +$405K 0.01% 960
2025
Q1 		$6.02M Sell
89,524
-537
-0.6% -$36.9K 0.01% 1260
2024
Q4 		$5.62M Buy
90,061
+23,742
+36% +$2.21M 0.01% 1367
2024
Q3 		$10.4M Buy
66,319
+18,674
+39% +$2.88M 0.01% 1026
2024
Q2 		$7.18M Buy
47,645
+1,783
+4% +$214K 0.01% 1189
2024
Q1 		$3.39M Buy
45,862
+301
+0.7% +$24.8K ﹤0.01% 1621
2023
Q4 		$3.6M Sell
45,561
-1,034
-2% -$62.4K ﹤0.01% 1602
2023
Q3 		$2.55M Buy
46,595
+1,123
+2% +$80.8K ﹤0.01% 1743
2023
Q2 		$3.82M Buy
45,472
+3,016
+7% +$231K ﹤0.01% 1540
2023
Q1 		$3.21M Buy
42,456
+2,421
+6% +$167K ﹤0.01% 1568
2022
Q4 		$2.47M Buy
40,035
+3,852
+11% +$205K ﹤0.01% 1674
2022
Q3 		$1.51M Buy
36,183
+5,234
+17% +$228K ﹤0.01% 1928
2022
Q2 		$973K Buy
30,949
+5,744
+23% +$153K ﹤0.01% 2156
2022
Q1 		$679K Buy
25,205
+1,621
+7% +$29K ﹤0.01% 2283
2021
Q4 		$452K Sell
23,584
-371
-2% -$9.3K ﹤0.01% 2550
2021
Q3 		$793K Buy
23,955
+1,166
+5% +$35.6K ﹤0.01% 2339
2021
Q2 		$756K Sell
22,789
-651
-3% -$18K ﹤0.01% 2371
2021
Q1 		$973K Sell
23,440
-886
-4% -$27.3K ﹤0.01% 2201
2020
Q4 		$484K Buy
24,326
+2,804
+13% +$41.5K ﹤0.01% 2457
2020
Q3 		$297K Buy
21,522
+214
+1% +$3.67K ﹤0.01% 2524
2020
Q2 		$382K Buy
21,308
+8,080
+61% +$126K ﹤0.01% 2454
2020
Q1 		$160K Buy
13,228
+2,371
+22% +$39.7K ﹤0.01% 2655
2019
Q4 		$206K Buy
+10,857
New +$199K ﹤0.01% 2736

Other funds holding TMDX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

RhumbLine Advisers's TMDX Position: Q1 2026 in Review

RhumbLine Advisers increased its Transmedics (TMDX) stake by 2% in Q1 2026, buying an estimated $233K and bringing the position to 89,824 shares worth $8.93M. The position accounts for 0.01% of the portfolio, ranked #1114.

RhumbLine Advisers first reported a position in TMDX in Q4 2019 and has held it in 26 quarters since. The position peaked at $12.5M in Q2 2025. 414 funds tracked by Wall St. Rank hold TMDX as of Q1 2026.

  • RhumbLine Advisers held 89,824 shares of Transmedics worth $8.93M as of Q1 2026.
  • RhumbLine Advisers bought 1,788 Transmedics shares in Q1 2026, an estimated $233K.
  • Transmedics made up 0.01% of RhumbLine Advisers's portfolio in Q1 2026, its #1114 holding.
  • RhumbLine Advisers first reported a position in Transmedics in Q4 2019 and has held it in 26 quarters since.
  • RhumbLine Advisers's Transmedics position peaked at $12.5M in Q2 2025.
  • 414 funds tracked by Wall St. Rank held Transmedics as of Q1 2026.

Based on RhumbLine Advisers's 13F filing for Q1 2026, filed 12 May 2026.